Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12919538 | 0.81 | POLB (0.47) | TDP1CYP11B1CYP11B2TAAR1IDO1 | |
| SCHEMBL23894563 | 0.79 | CYP11B1 (0.44) | CYP11B1ADRA2CCYP11B2SIGMAR1MAOB | |
| SCHEMBL973852 | 0.79 | IDO1 (0.41) | IDO1SIGMAR1FAAH | |
| SCHEMBL13950383 | 0.77 | SIGMAR1 (0.46) | TDP1SIGMAR1 | |
| SCHEMBL13950382 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2TDP1CYP11B1ADRA2CCYP11B2 | |
| SCHEMBL14409112 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2TDP1CYP11B1ADRA2CCYP11B2 | |
| SCHEMBL152660 | 0.76 | CYP19A1 (0.48) | CYP11B1CYP11B2KMT2AFAAH | |
| SCHEMBL974030 | 0.73 | KDM4E (0.51) | KDM4EMAOBFAAH | |
| SCHEMBL23003843 | 0.73 | SMN1; SMN2 (0.51) | SMN1; SMN2TDP1CYP11B1ADRA2CCYP11B2 | |
| SCHEMBL23894566 | 0.72 | SMN1; SMN2 (0.39) | SMN1; SMN2TDP1CYP11B1ADRA2CCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4851440-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| US-7658910-B2 | Preparation of radiolabelled haloaromatics via polymer-bound intermediates | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2010-02-09 | — | — | US | claimed |
| EP-1723140-B1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | claimed |
| US-20080085984-A1 | PREPARATION OF RADIOLABELLED HALOAROMATICS VIA POLYMER-BOUND INTERMEDIATES | THE UNIVERSITY OF WESTERN ONTARIO | 2008-04-10 | — | — | US | claimed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | claimed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| EP-1571150-A1 | Process for the preparation of tryptase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | claimed |
| US-20030012730-A1 | Preparation of radiolabelled haloaromatics via polymer-bound intermediates | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2003-01-16 | — | — | US | claimed |
| WO-1999018053-A1 | PREPARATION OF RADIOLABELLED HALOAROMATICS VIA POLYMER-BOUND INTERMEDIATES | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 1999-04-15 | — | — | WO | claimed |
| US-20240174782-A1 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF | MOLECULAR INSIGHT PHARM INC (US) | 2024-05-30 | — | — | US | disclosed |
| US-11840592-B2 | Preparations of meta-iodobenzylguanidine and precursors thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840592-B2 | Preparations of meta-iodobenzylguanidine and precursors thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840592-B2 | Preparations of meta-iodobenzylguanidine and precursors thereof | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230008878-A1 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF | CITIZENS BANK, N.A., AS COLLATERAL AGENT, NATIONAL BANKING ASSOCIATION | 2023-01-12 | — | — | US | disclosed |
| US-20040260073-A1 | Methods for purifying radiolabelled compounds | MCMASTER UNIVERSITY (CA) | 2004-12-23 | — | — | US | disclosed |
| WO-2004035744-A2 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | BIOSTREAM, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-20030012730-A1 | Preparation of radiolabelled haloaromatics via polymer-bound intermediates | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2003-01-16 | — | — | US | disclosed |
| US-6461585-B1 | DIAGNOSTICS AND ANTITUMOR | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 2002-10-08 | — | — | US | disclosed |
| WO-1999018053-A1 | PREPARATION OF RADIOLABELLED HALOAROMATICS VIA POLYMER-BOUND INTERMEDIATES | THE UNIVERSITY OF WESTERN ONTARIO (CA) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008878-A1 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF | NISCH, TPO, UGT1A9 | SMN1; SMN2 1517/4885TDP1 1578/4885CYP11B1 2266/4885 |
| US-20030012730-A1 | Preparation of radiolabelled haloaromatics via polymer-bound intermediates | MPI, HDHD5, IPO5 | SMN1; SMN2 4799/4885TDP1 742/4885CYP11B1 510/4885 |
| US-20240174782-A1 | PREPARATIONS OF META-IODOBENZYLGUANIDINE AND PRECURSORS THEREOF | NISCH, TPO, UGT1A9 | SMN1; SMN2 1517/4885TDP1 1578/4885CYP11B1 2266/4885 |
| US-11840592-B2 | Preparations of meta-iodobenzylguanidine and precursors thereof | NISCH, TPO, UGT1A9 | SMN1; SMN2 1517/4885TDP1 1578/4885CYP11B1 2266/4885 |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | CMA1, TPSAB1, TPSB2 | SMN1; SMN2 2159/4885TDP1 2332/4885CYP11B1 916/4885 |
| US-20040260073-A1 | Methods for purifying radiolabelled compounds | PAICS, PFAS, NPEPPS | SMN1; SMN2 4577/4885TDP1 2547/4885CYP11B1 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.